Roche Holding recently reported positive Phase II results for CT-388, its once-weekly dual GLP-1/GIP obesity drug candidate, showing clinically meaningful placebo-adjusted weight loss and favorable tolerability over 48 weeks.
The data suggest CT-388 could become an important pillar in Roche’s expanding cardiometabolic portfolio, complementing its diagnostics capabilities in managing obesity-related health risks.
We’ll now examine how CT-388’s Phase II success, and its potential move into late-stage trials, shapes Roche’s investment narrative.
We’ve found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
For me, the core Roche story is about backing a diversified healthcare group that is leaning on a deep pipeline, high return on equity and a long record of growing dividends, even as it works through mixed earnings trends and a high debt load. The latest CT-388 Phase II success adds a fresh cardiometabolic growth option, but the share price reaction so far has been measured, suggesting investors still see nearer term catalysts anchored in execution on late stage oncology and immunology launches, delivery against Roche’s mid single digit sales and high single digit EPS guidance for 2026, and how pricing pressures in diagnostics and products like Xolair evolve. CT-388 now sits alongside those factors as a meaningful, but still early, piece of the puzzle rather than the main driver.
However, one risk stands out that shareholders may not be fully focusing on yet. Despite retreating, Roche Holding’s shares might still be trading above their fair value and there could be some more downside. Discover how much.
SWX:ROG 1-Year Stock Price Chart
Eight fair value estimates from the Simply Wall St Community span roughly CHF 302 to a very large CHF 760, underlining how far apart individual views can be. Set against that spread, Roche’s reliance on steady mid single digit sales and high single digit EPS growth guidance, alongside execution risk in its obesity and late stage oncology portfolios, gives you plenty of moving parts to weigh as you compare those community numbers with your own expectations.
Explore 8 other fair value estimates on Roche Holding – why the stock might be worth 13% less than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com